


Viramal Limited Revenue
Pharmaceutical Manufacturing • London, England, United Kingdom • 11-20 Employees
Viramal Limited revenue & valuation
| Annual revenue | $1,197,770 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $3,900,000 |
| Total funding | No funding |
Key Contacts at Viramal Limited
Oliver Bates
Ceo
Enda Mcveigh
Non Executive Director
Ken Roberts
Quality Director
Ken Roberts
Director Of Quality
Company overview
| Headquarters | 22 South Molton Street, London, W1K 5RB, GB |
| Phone number | +442074953052 |
| Website | |
| NAICS | 3254 |
| SIC | 283 |
| Keywords | Endometriosis, Women'S Health, Hormones, Fertility, Hormone Replacement Therapy, Contraceptives, Otc Products, Transdermal Delivery, Male & Female Sexual Health, Vaginal Delivery |
| Founded | 2013 |
| Employees | 11-20 |
| Socials |
Viramal Limited Email Formats
Viramal Limited uses 1 email format. The most common is {first initial}{last name} (e.g., jdoe@viramal.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@viramal.com | 100% |
About Viramal Limited
Viramal is a Specialty Pharmaceutical Company developing a portfolio of therapies in the fields of male & female sexual health focussing on the utilisation and application of sex steroid hormones. Viramal’s patent protected technology platform facilitates superior drug delivery both transdermally and to sensitive female reproductive areas with an outstanding safety profile. Similar to cosmetic creams, Viramal’s products have excellent patient acceptability, and unlike competitors does not require alcohol for API solubility or absorption enhancement. All of the Company’s products benefit from the avoidance of the First Hepatic Pass, and the safety/ metabolite concerns that result other marketed products, particularly in Menopausal Hormone Therapy. The portfolio is made up of products in the following area’s: 1. Sex Steroid Hormone Deficiencies * Testosterone Replacement for Men * Menopausal Hormone Therapy 2. Reproductive & Fertility * Fertility Support * Endometriosis & Fibromyomas – treating symptoms and enabling fertility within women of reproductive age 3. Contraception & General Sexual Health * Safer and more patient-acceptable daily & emergency contraceptives * Gynaecological health Viramal’s lead product, TestoCream, is expected to be filed for a New Drug Application to the FDA in the US in 2017/18. TestoCream is a testosterone replacement therapy, similar to a cosmetic cream, applied to the skin. Unlike competing products, TestoCream is neither messy nor watery, requiring a smaller area for application, and it is also quick drying. Testosterone is only soluble in alcohol, with competing products having an alcohol content of around 70% or more. TestoCream offers a far safer alternative, having less than 3.5% alcohol, reducing the risk of skin irritation.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Viramal Limited has 4 employees across 2 departments.
Departments
Number of employees
Funding Data
Viramal Limited has never raised funding before.
Viramal Limited Tech Stack
Discover the technologies and tools that power Viramal Limited's digital infrastructure, from frameworks to analytics platforms.
Security
JavaScript libraries
Tag managers
Reverse proxies
Cookie compliance
JavaScript libraries
UI frameworks
Analytics
Maps
Frequently asked questions
4.8
40,000 users



